Premium
Pharmaceutical Prod Dev (MM) (PPDI)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
PPD, Inc. (Nasdaq: PPD) was named one of the “Best Workplaces in Greater China™ 2021” by Great Place to Work® for successfully creating an inclusive workplace experience for employees. PPD has...
PPD, Inc. (Nasdaq: PPD) was named “Best Vaccine CRO of the Year” at the Asia-Pacific Vaccine Excellence Awards 2021 for its strong presence, extensive experience and quality delivery in the...
PPD, Inc. (Nasdaq: PPD) earned numerous honors at the 2021 PharmaTimes Clinical Researcher of the Year-The Americas competition. Two PPD teams won gold, one team won silver and another team took...
PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, today reported its financial results for the third quarter ended September 30, 2021. Highlights Net authorizations...
PPD, Inc. (Nasdaq: PPD) was named “Clinical Research Company of the Year” at the 2021 PharmaTimes Clinical Researcher of the Year International competition in London. In addition to PPD winning...
PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, will host a conference call on Thursday, October 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its third quarter...
PPD, Inc. (Nasdaq: PPD) is the recipient of the 2021 Eagle Award from the Society for Clinical Research Sites (SCRS) for its commitment to advancing clinical research professionalism through...
PPD, Inc. (Nasdaq: PPD) has been recognized with two global excellence awards for its effective learning programs, honoring the company’s high-performing employee development initiatives...
PPD, Inc. (Nasdaq: PPD) has been recognized as one of the best in the world for its successful employee learning and development programs by the Association for Talent Development (ATD), a global...
PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, today reported its financial results for the second quarter ended June 30, 2021. Highlights Net authorizations growth of...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
